Thilo Schroeder, Ph.D. has a passion for precision medicines in cancer with a focus on identifying first and best-in-class targeted therapies regardless of drug modality. Since 2012, Thilo has helped grow and shape Nextech as a leading oncology focused venture firm.

Thilo is a board member of Revolution Medicines (NASDAQ: RVMD), Circle Pharma, Atavistik Bio, MOMA Therapeutics, Exo Therapeutics and Synnovation Therapeutics. Past board seats include Blueprint Medicines (NASDAQ: BPMC), Silverback Therapeutics (NASDAQ: SBTX), Peloton Therapeutics (acquired by Merck (NYSE: MRK)), PMV Pharma (NASDAQ: PMVP), Alterome Therapeutics and IDEAYA Bioscience (NASDAQ: IDYA). Past observer seats include Cargo Therapeutics (NASDAQ: CRGX) and Black Diamond Therapeutics (NASDAQ: BDTX).

Thilo began his biotech career at the pioneering cancer immunology company Micromet (acquired by Amgen (NASDAQ: AMGN)) while studying at Ecole Supérieure de Biotechnologie de Strasbourg, conducted research at the University of Sydney and obtained his Ph.D. from the University of Zurich, focused on protein engineering in the development of Designed Ankyrin Repeat Proteins (DARPins), a technology developed by Molecular Partners (SWX: MOLN).

A family person and loving father of two, Thilo has not given up on the illusion of staying fit, and can often be found at the nearest CrossFit gym when he travels.